Xbrane Biopharma AB (publ) reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was SEK 51.12 million compared to SEK 18.87 million a year ago. Net loss was SEK 91.01 million compared to SEK 33.78 million a year ago. Basic loss per share from continuing operations was SEK 3.21 compared to SEK 1.32 a year ago. Diluted loss per share from continuing operations was SEK 3.21 compared to SEK 1.32 a year ago. Basic loss per share was SEK 3.22 compared to SEK 1.35 a year ago. Diluted loss per share was SEK 3.22 compared to SEK 1.35 a year ago.
For the six months, sales was SEK 112.95 million compared to SEK 26.2 million a year ago. Net loss was SEK 149.41 million compared to SEK 69.9 million a year ago. Basic loss per share from continuing operations was SEK 5.33 compared to SEK 2.82 a year ago. Diluted loss per share from continuing operations was SEK 5.33 compared to SEK 2.82 a year ago. Basic loss per share was SEK 5.36 compared to SEK 2.79 a year ago. Diluted loss per share was SEK 5.36 compared to SEK 2.79 a year ago.